Search results for "benefits"
Yesterday, the Scottish Medicines Consortium approved the use of tisagenlecleucel-T (brand name Kymriah), on the NHS in Scotland, for patients with diffuse large-B cell lymphoma (DLBCL). Kymriah is a brand of CAR-T cell therapy.
The Scottish Medicine Consortium (SMC) has announced that it is recommending the use of venetoclax with rituximab on the NHS for chronic lymphocytic leukaemia (CLL) patients who have had at least one prior therapy. Read more about this decision in our article.
Today, the Scottish Medicines Consortium (SMC) has not approved the use of Tisagenlecleucel-T (brand name Kymriah) on the NHS in Scotland for patients with diffuse large-B cell lymphoma (DLBCL). Kymriah is a brand of chimeric antigen receptor (CAR) T-cell therapy and is manufactured by Novartis.
There are over 1,600 children diagnosed with cancer in the UK each year – approximately a third are diagnosed with leukaemia. A leukaemia diagnosis has a huge impact on you, your child and the rest of your family - what follows is usually a very emotional and distressing time and lives are often turned upside down.